IWR-1

Synonyms: endo-IWR 1; IWR-1-endo
IWR-1 (IWR-1-endo) 是一种靶向 Wnt/β-catenin 的 tankyrase 抑制剂 (IC50 = 180 nM),它参与经典 Wnt 信号转导的关键步骤,即 β-catenin 转位至细胞核并随后激活 TCF/LEF 及表达 Wnt/β-catenin 下游靶标,同时通过增强 Axin 支架破坏复合物的稳定性来促进 β-catenin 磷酸化,可用于抗肿瘤研究以及骨肉瘤、结直肠癌和牛皮癣等疾病的研究。
产品编号: MS-Z78387 纯度: 99.60% CAS No.: 1127442-82-3 分子式: C25H19N3O3 分子量: 409.44
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
25mg
询价
3-5 天
50mg
询价
3-5 天
100mg
询价
3-5 天
200mg
询价
询价
500mg
询价
询价

产品描述

IWR-1 (IWR-1-endo) 是一种靶向 Wnt/β-catenin 的 tankyrase 抑制剂 (IC50 = 180 nM),它参与经典 Wnt 信号转导的关键步骤,即 β-catenin 转位至细胞核并随后激活 TCF/LEF 及表达 Wnt/β-catenin 下游靶标,同时通过增强 Axin 支架破坏复合物的稳定性来促进 β-catenin 磷酸化,可用于抗肿瘤研究以及骨肉瘤、结直肠癌和牛皮癣等疾病的研究。

生物实验数据

生物活性 IWR-1 (IWR-1-endo) is a tankyrase inhibitor targeting Wnt/β-catenin (IC50 = 180 nM) that participates in a key step of canonical Wnt signal transduction, namely the translocation of β-catenin to the nucleus followed by activation of TCF/LEF and expression of Wnt/β-catenin downstream targets, and promotes β-catenin phosphorylation by enhancing the stability of the Axin scaffold destruction complex, making it useful for antitumor research as well as studies on diseases such as osteosarcoma, colorectal cancer, and psoriasis.
IC50 & Target HT29 cells:24.4 μM, SW48 cells:2.5 μM (EC50), SW48 cells:0.25 μM, Wnt:0.2 μM (EC50), HEK293T cells:26 nM
体外研究
(In Vitro)

IWR-1 对骨肉瘤癌干细胞样细胞 (CSC) 具有细胞毒性。
IWR-1 可抑制结直肠癌细胞系的细胞迁移、侵袭和基质金属蛋白酶活性。
IWR-1 (2.5-10 μM,48-96 小时) 能够有效降低 MG-63 和 MNNG-HOS 细胞系来源的细胞球以及亲本细胞球中的细胞球活力,且这种降低呈浓度和时间依赖性。
IWR-1 (10 μM,96 小时) 可增加 TUNEL 阳性细胞的数量,在 96 小时时与对照组相比分别增加 4.65 倍和 15.83 倍,并促进 caspases 3/7 的活化,在 MG-63 和 MNNG-HOS 细胞球中分别增加 2.15 倍和 1.27 倍。
IWR-1 (10 μM,48 小时) 可诱导 MG-63 和 MNNG-HOS 细胞系来源的细胞球细胞周期停滞在 G2/M 期,并增加 S 期细胞占比。
IWR-1 (10 μM,48 小时) 可抑制 MG-6t4 和 MNNG-HOS 细胞中第一代 7 天龄球体的次级球体形成率,分别约为 53% 和 55%。
IWR-1 (5-50 μM,24-48 小时) 以剂量和时间依赖性方式降低 HCT116 细胞的增殖。
IWR-1 (5-50 μM,24-48 小时) 可抑制 TNF-α 刺激的 HCT116 和 HT29 细胞迁移。

Western Blot Analysis

Cell Line: MG-63 and MNNG-HOS spheres and parent cells
Concentration: 10 μM
Incubation Time: 96 h
Result: Led to an upregulation of Bak and a downregulation of Bcl-2 (key proteins involved in mitochondrial-dependent apoptosis), which contributes to a Bak/Bcl-2 ratio >1 that prone the cells to undergo apoptosis.
Resulted in a higher β-catenin nuclear/cytoplasmic ratio in spheres, indicating an increased Wnt/β-catenin pathway activation in osteosarcoma spheres.
Stabilized Axin2 protein levels.
Diminished the protein expression levels of Cyclin D1 in both parental cells and spheres.

RT-PCR

Cell Line: MG-63 and MNNG-HOS spheres and parent cells
Concentration: 10 μM
Incubation Time: 96 h
Result: Led to an upregulation of Bak and a downregulation of Bcl-2 (key proteins involved in mitochondrial-dependent apoptosis), which contributes to a Bak/Bcl-2 ratio >1 that prone the cells to undergo apoptosis.
Results in a higher β-catenin nuclear/cytoplasmic ratio in spheres, indicating an increased Wnt/β-catenin pathway activation in osteosarcoma spheres.
Stabilized Axin2 protein levels.
Diminished the protein expression levels of Cyclin D1 in both parental cells and spheres.

Cell Viability Assay

Cell Line: MG-63 and MNNG-HOS spheres and parent cells
Concentration: 2.5, 5, 7.5, 10 μM
Incubation Time: 48 and 96 h
Result: Reduced cell viability when concentration is higher than 5 μM.
Elicited more than 70% reduction of cell viability in spheres derived from the two cell lines at 96 h with 10 μM.
Had minimal effect on parental cells since the Wnt/β-catenin signaling is absent in these cells.
Increased the susceptibility of spheres towards Doxorubicin (MS-B38737) when treated in combination with increasing concentrations of Doxorubicin (0.01-100 μM).

Western Blot Analysis

Cell Line: HCT116 cells
Concentration: 5, 10, 20, 50 μM
Incubation Time: 0, 4, 8, 24, 48 h
Result: Increased the levels of the epithelial marker E-cadherin whilst decreased the mesenchymal markers N-cadherin, Vimentin, and Snail dose- and time-dependently.
Inhibited the EMT process in HCT116 cells effectively.
Decreased β-catenin expression and inhibited the EMT-like expressional changes whereby decreasing N-cadherin and Snail and increasing E-cadherin expressions, even in the presence of TNF-α (MS-R26275) (10 ng/mL for 24 h)-induced EMT stimulation.
Decreased the phosphorylation of Akt in a concentration- and time-dependent manner.
Decreased the surviving expression in a concentration- and time-dependent manner, thereby promoting tumor proliferation directly or indirectly through regulating cancer cell homeostasis.
Reduced MMP activities only when surviving was suppressed.

Real Time qPCR

Cell Line: HCT116 cells
Concentration: 5, 10, 20, 50 μM
Incubation Time: 0, 4, 8, 24, 48 h
Result: Inhibited EMT in the mRNA levels under the TNF-α-induced EMT stimulation.
体内研究
(In Vivo)

IWR-1 (5 mg/kg,瘤内注射,每天两次,共注射 12 天) 可显著抑制骨肉瘤小鼠模型中的肿瘤生长。
IWR-1 (10 mg/kg,皮下注射,第 1、3、5 天) 可改善 Imiquimod (MS-W79117) 诱发的银屑病样小鼠模型中 IL-36γ (2 μg/只小鼠,第 1、3、5 天) 介导的银屑病皮肤病变加重。

Animal Model: Immunocompromised nude mice (6-week old female Swiss nude) were injected sub-cutaneously the pGL4-transfected MNNG-HOS cells (2×106 cells/100 mL PBS)
Dosage: 5 mg/kg
Administration: Intratumorally, each 2 d for 12 d
Result: Resulted in slower tumor growth rate and reduction in tumor size by 73% and 71% in comparison to control and to Doxorubicin-treated (8 mg/kg, i.p., each 4 d for 12 d) groups.
Enhanced the therapeutic efficacy of Doxorubicin shown by a greater reduction of tumor burden at the end of the treatment in opposite to Doxorubicin alone.
Animal Model: Balb/c mice (aged 6-8 weeks) with shaven back and treated with a daily topical dose of IMQ cream
Dosage: 10 mg/kg
Administration: Subcutaneous injection (s.c.) on days 1, 3, 5
Result: Increased epidermal thickening with keratinocyte thickness.
Significantly diminished the effect of IMQ on hyperplasia in the IMQ+IWR-1 group.
Ameliorated the pathological changes in IL-36γ-induced psoriasiform skin lesion.
Reversed IL-36γ-mediated upregulation of inflammatory factors (IL-17 A and IFN-γ) in psoriatic lesions.
Reversed IL-36γ-mediated upregulation of β-catenin and DKK1 expression.
性状 固体
颜色 Off-white to yellow

化学信息

分子量 409.44
分子式 C25H19N3O3
CAS No. 1127442-82-3
别名 endo-IWR 1; IWR-1-endo

储存&溶解度

体内实验配方
10% DMSO+40% PEG300+ 5% Tween 80 + 45% Saline: 4.29 mg/mL (10.48 mM), Suspension.
10% DMSO+90% Saline: < 4.29 mg/mL (10.48 mM), Lower concentrations may be soluble, but exact solubility limit is unknown.
10% DMSO+40% PEG300+5% Tween 80+45% Saline: 4.1 mg/mL (10.01 mM), Suspension.
请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。
储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 2 years
-20°C 1 year
运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 50 mg/mL (122.12 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM2.4424 mL12.2118 mL24.4236 mL61.0590 mL
5 mM0.4885 mL2.4424 mL4.8847 mL12.2118 mL
10 mM0.2442 mL1.2212 mL2.4424 mL6.1059 mL
15 mM0.1628 mL0.8141 mL1.6282 mL4.0706 mL
20 mM0.1221 mL0.6106 mL1.2212 mL3.0530 mL
25 mM0.0977 mL0.4885 mL0.9769 mL2.4424 mL
30 mM0.0814 mL0.4071 mL0.8141 mL2.0353 mL
40 mM0.0611 mL0.3053 mL0.6106 mL1.5265 mL
50 mM0.0488 mL0.2442 mL0.4885 mL1.2212 mL
60 mM0.0407 mL0.2035 mL0.4071 mL1.0177 mL
80 mM0.0305 mL0.1526 mL0.3053 mL0.7632 mL
100 mM0.0244 mL0.1221 mL0.2442 mL0.6106 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 2 years; -20°C, 1 year。-80°C储存时,请在2年内使用, -20°C储存时,请在1年内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础